Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIRCULATE-III: ctDNA-Guided Adjuvant Chemotherapy in Stage III Colorectal Cancer
NCT07340567Phase 3Active, not recruiting
- Sponsor
- Unicancer
- Start
- Jul 2026
- Primary completion
- Nov 2032
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of capecitabine, oxaliplatin, FOLFIRINOX, FOLFOX in colorectal cancer (CRC), sponsored by Unicancer. Started Jul 2026; status: active, not recruiting.
02
Drugs
capecitabineoxaliplatinFOLFIRINOXFOLFOX
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07340567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07340567.